Serodus ApS has received additional SER130 pharmacological results. The General Annual Meeting was held in Oslo on 9th June 2026 and the Annual Report 2025 was approved without comments. Read…

Serodus ApS has received additional SER130 pharmacological results. Read more here

Serodus ApS will receive additional pharmacological reports from last studies with SER130. Shareholder meeting will be held in Q1 or Q2 2026 Read more here

Serodus ApS will receive final pharmacological reports from last studies with SER130. Shareholder meeting will be held in Q1 2026. Read more here

Serodus ApS has initiated sale of SER150. Serodus ApS will finalize the pharmacological studies of SER130. Read more here

Draft report SER150 CL-009 was received and will be discussed with the Australian contract organisation and the Serodus biostatistician consultant. In March 2025 the company launched a Private Placement with…

Download investor letter here

Download the minutes here

Download notice here

Unblinding of the database after SER150 CL-009 was delayed. Calculation of SER150 effect on kidney function compared to placebo is consequently also delayed. Read more here